Patrick Machado

CIK: 0001311210

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)1 (3.8%)

Derivative conversions

Awards (A)11 (42.3%)

Compensation grants

Other (G, F, J, C, D, …)14 (53.8%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (5)

ALMS

ALUMIS INC.

Director

RCUS

Arcus Biosciences, Inc.

Director

XENE

Xenon Pharmaceuticals Inc.

Director

ADVM

Adverum Biotechnologies, Inc.

Director

SLRN

ACELYRIN, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (26 total)

ALMS
ALUMIS INC.
Jun 30, 2026
Award(A)
Direct
3.6K shares-
RCUS
Arcus Biosciences, Inc.
Jun 11, 2026
Award(A)
Direct
5.7K shares-
XENE
Xenon Pharmaceuticals Inc.
Jun 3, 2026
Award(A)
Share Option (Right to Buy)
Direct
10.5K shares-
XENE
Xenon Pharmaceuticals Inc.
Jun 3, 2026
Award(A)
Restricted Share Units
Direct
1.6K shares-
XENE
Xenon Pharmaceuticals Inc.
Jun 1, 2026
Exercise(M)
Direct
2.6K shares-
ADVM
Adverum Biotechnologies, Inc.
Dec 9, 2025
Disposition(D)
Stock Option (Right to Buy)
Direct
6.5K shares-
ADVM
Adverum Biotechnologies, Inc.
Dec 9, 2025
Disposition(D)
Stock Option (Right to Buy)
Direct
3.4K shares-
ADVM
Adverum Biotechnologies, Inc.
Dec 9, 2025
Disposition(D)
Stock Option (Right to Buy)
Direct
3.5K shares-
ADVM
Adverum Biotechnologies, Inc.
Dec 9, 2025
Disposition(D)
Stock Option (Right to Buy)
Direct
4.5K shares-
ADVM
Adverum Biotechnologies, Inc.
Dec 9, 2025
Disposition(D)
Stock Option (Right to Buy)
Direct
1.5K shares-
ADVM
Adverum Biotechnologies, Inc.
Dec 9, 2025
Disposition(D)
Stock Option (Right to Buy)
Direct
3K shares-
ADVM
Adverum Biotechnologies, Inc.
Dec 9, 2025
Disposition(D)
Stock Option (Right to Buy)
Direct
5.3K shares-
ADVM
Adverum Biotechnologies, Inc.
Dec 9, 2025
Disposition(D)
Stock Option (Right to Buy)
Direct
5.3K shares-
ADVM
Adverum Biotechnologies, Inc.
Dec 9, 2025
Disposition(D)
Stock Option (Right to Buy)
Direct
5.3K shares-
ADVM
Adverum Biotechnologies, Inc.
Dec 9, 2025
Tender Offer(U)
Direct
8.8K shares-
ADVM
Adverum Biotechnologies, Inc.
Dec 9, 2025
Disposition(D)
Stock Option (Right to Buy)
Direct
13.6K shares-
ADVM
Adverum Biotechnologies, Inc.
Dec 9, 2025
Disposition(D)
Stock Option (Right to Buy)
Direct
13.8K shares-
ADVM
Adverum Biotechnologies, Inc.
Dec 9, 2025
Disposition(D)
Stock Option (Right to Buy)
Direct
1K shares-
ALMS
ALUMIS INC.
Jul 30, 2025
Award(A)
Stock Option (Right to Buy)
Direct
49.8K shares-
ADVM
Adverum Biotechnologies, Inc.
Jun 17, 2025
Award(A)
Stock Option (Right to Buy)
Direct
3.1K shares-
ADVM
Adverum Biotechnologies, Inc.
Jun 17, 2025
Award(A)
Stock Option (Right to Buy)
Direct
10.5K shares-
RCUS
Arcus Biosciences, Inc.
Jun 10, 2025
Award(A)
Direct
13.3K shares-
XENE
Xenon Pharmaceuticals Inc.
Jun 5, 2025
Award(A)
Restricted Share Units
Direct
2.6K shares-
XENE
Xenon Pharmaceuticals Inc.
Jun 5, 2025
Award(A)
Share Option (Right to Buy)
Direct
17K shares-
SLRN
ACELYRIN, Inc.
May 21, 2025
Disposition(D)
Indirect
14.7K shares-

		Type	Shares	Price		Ownership
Jun 30, 2026	ALMS ALUMIS INC.	Award(A)	3,553	-	$0	Direct
Jun 11, 2026	RCUS Arcus Biosciences, Inc.	Award(A)	5,700	-	$0	Direct
Jun 3, 2026	XENE Xenon Pharmaceuticals Inc.	Award(A) Share Option (Right to Buy)	10,507	-	-	Direct
Jun 3, 2026	XENE Xenon Pharmaceuticals Inc.	Award(A) Restricted Share Units	1,593	-	-	Direct
Jun 1, 2026	XENE Xenon Pharmaceuticals Inc.	Exercise(M)	2,645	-	$0	Direct
Dec 9, 2025	ADVM Adverum Biotechnologies, Inc.	Disposition(D) Stock Option (Right to Buy)	6,476	-	-	Direct
Dec 9, 2025	ADVM Adverum Biotechnologies, Inc.	Disposition(D) Stock Option (Right to Buy)	3,360	-	-	Direct
Dec 9, 2025	ADVM Adverum Biotechnologies, Inc.	Disposition(D) Stock Option (Right to Buy)	3,500	-	-	Direct
Dec 9, 2025	ADVM Adverum Biotechnologies, Inc.	Disposition(D) Stock Option (Right to Buy)	4,500	-	-	Direct
Dec 9, 2025	ADVM Adverum Biotechnologies, Inc.	Disposition(D) Stock Option (Right to Buy)	1,500	-	-	Direct
Dec 9, 2025	ADVM Adverum Biotechnologies, Inc.	Disposition(D) Stock Option (Right to Buy)	3,000	-	-	Direct
Dec 9, 2025	ADVM Adverum Biotechnologies, Inc.	Disposition(D) Stock Option (Right to Buy)	5,250	-	-	Direct
Dec 9, 2025	ADVM Adverum Biotechnologies, Inc.	Disposition(D) Stock Option (Right to Buy)	5,250	-	-	Direct
Dec 9, 2025	ADVM Adverum Biotechnologies, Inc.	Disposition(D) Stock Option (Right to Buy)	5,250	-	-	Direct
Dec 9, 2025	ADVM Adverum Biotechnologies, Inc.	Tender Offer(U)	8,818	-	-	Direct
Dec 9, 2025	ADVM Adverum Biotechnologies, Inc.	Disposition(D) Stock Option (Right to Buy)	13,590	-	-	Direct
Dec 9, 2025	ADVM Adverum Biotechnologies, Inc.	Disposition(D) Stock Option (Right to Buy)	13,820	-	-	Direct
Dec 9, 2025	ADVM Adverum Biotechnologies, Inc.	Disposition(D) Stock Option (Right to Buy)	1,000	-	-	Direct
Jul 30, 2025	ALMS ALUMIS INC.	Award(A) Stock Option (Right to Buy)	49,800	-	-	Direct
Jun 17, 2025	ADVM Adverum Biotechnologies, Inc.	Award(A) Stock Option (Right to Buy)	3,140	-	-	Direct
Jun 17, 2025	ADVM Adverum Biotechnologies, Inc.	Award(A) Stock Option (Right to Buy)	10,450	-	-	Direct
Jun 10, 2025	RCUS Arcus Biosciences, Inc.	Award(A)	13,300	-	-	Direct
Jun 5, 2025	XENE Xenon Pharmaceuticals Inc.	Award(A) Restricted Share Units	2,645	-	-	Direct
Jun 5, 2025	XENE Xenon Pharmaceuticals Inc.	Award(A) Share Option (Right to Buy)	17,012	-	-	Direct
May 21, 2025	SLRN ACELYRIN, Inc.	Disposition(D)	14,675	-	-	Indirect

1-25 of 26 transactions

About Machado Patrick

Machado Patrick (SEC CIK 0001311210) files insider reports with the SEC as Director of ALUMIS INC. (ALMS), Director of Arcus Biosciences, Inc. (RCUS) and Director of Xenon Pharmaceuticals Inc. (XENE). Signal8 also holds filings tied to 2 other companies.

Signal8 holds 10 ownership filings by Machado Patrick, all Form 4s, filed between May 23, 2025 and Jul 2, 2026. Those filings report 26 transactions, from May 21, 2025 to Jun 30, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Machado Patrick's filings is in SOUTH SAN FRANCISCO, CA.

Recent filings by Machado Patrick

Jun 30, 2026: Grant or award of ALMS shares (Form 4, code A).
Jun 11, 2026: Grant or award of RCUS shares (Form 4, code A).
Jun 3, 2026: Grants or awards of XENE derivative securities (2 lines, Form 4, code A).
Jun 1, 2026: Option exercise of XENE shares (Form 4, code M).
Dec 9, 2025: Disposition to issuer transactions of ADVM derivative securities (9 lines, Form 4, code D).

Other insiders filing for ALUMIS INC. (ALMS)

AKKARAJU SRINIVAS, Director
Schroer John R., Chief Financial Officer
Pangali Sanam, Chief Legal Officer
Hardiman Roy C., Chief Business & Strategy Ofcr
Goldstein David M, Chief Scientific Officer
Drappa Jorn, Chief Medical Officer

How to read Form 4 transaction codes